November 21, 2012 By Alison Knopf, Contributing Writer
article
When violence stems from mental illness, meds may be the first step in treatment.
October 29, 2012 Dennis Grantham, Editor-in-Chief
news
With Hurricane Sandy bearing down, NY State Medicaid office relaxes certain authorization requirements to speed care
October 18, 2012 Dennis Grantham, Editor-In-Chief
article
Tool offers help to psychiatrists with “difficult-to-treat” patients.
October 10, 2012 Shannon Brys, Associate Editor
news
In coordination with World Mental Health Week, a new website has been launched that endorses an integrative approach to the treatment of mental health.
March 15, 2012 Nick Zubko, Associate Editor
blog
Since it was approved by the FDA in 2002, Lexapro (escitalopram) has become a widely prescribed medication to treat both depression and generalized anxiety disorder in adults. Yesterday, the agency approved the first generic version of the drug.
March 9, 2012 Nick Zubko, Associate Editor
blog
This week, a federal court handed down a five-year prison sentence to the FDA chemist who used his access to the agency's drug approval process for insider trading. Information on pending mental health medications accounted for a large portion of his profits.
March 7, 2012 News release
news
Alkermes has appointed Mark Stejbach as its new chief commercial officer. In this newly created role, Stejbach will be responsible for Alkermes' commercial activities, including marketing and sales of Vivitrol.
February 24, 2012 Nick Zubko, Associate Editor
blog
The American Psychiatric Association has issued a statement slamming the segment that aired on “60 Minutes” this Sunday, which featured Harvard psychologist Irving Kirsch discussing a study he claims shows that placebos are “just as effective” as antidepressants in the treatment of depression.
February 21, 2012 Nick Zubko, Associate Editor
blog
If you didn’t see "60 Minutes" this past Sunday, you missed an interesting piece. The program interviewed Harvard scientist Irving Kirsch, a psychologist whose research is raising questions about how effective antidepressants really are.
February 15, 2012 News release
news
Forest Laboratories and Gedeon Richter have announced preliminary top-line results from a Phase III clinical trial of Cariprazine (RGH-188), an investigational antipsychotic agent, in patients with acute mania associated with bipolar I disorder.
February 2, 2012 Dennis Grantham, Editor-in-Chief
blog
For years, mental health providers have worried about the incidence of "metabolic syndrome" among consumers taking atypical antipsychotic meds for serious mental illness. Now, a study has identified the link.
February 1, 2012 Nick Zubko, Associate Editor
blog
It’s hard to believe that psychiatric meds are anything but a “growth industry,” but that’s not really the case anymore, at least according to new research from Thomson Reuters and SAMHSA.
